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ABSTRACT—By 1981, 11% of married women in Costa Rica ages 
20-49 years had used depot-medroxyprogesterone acetate (DMPA) 
and 58% had used oral contraceptives (OCs). Since 1977, the 
Costa Rican Ministry of Health has maintained a nationwide 
cancer registry. These circumstances provided an opportunity for 
a population-based, case-control study of DMPA, OCs, and breast 
cancer in Costa Rica. Cases were 171 women ages 25-58 years 
with breast cancer diagnosed between 1982 and 1984; controls 
were 826 women randomly chosen during a nationwide household 
survey. Cases and controls were interviewed with the use of a 
standard questionnaire covering their reproductive and contracep-
tive histories. Logistic regression methods were used to adjust for 
confounding factors. While few cases or controls had ever used 
DMPA, DMPA users had an elevated relative risk (RR) estimate of 
breast cancer of 2.6 (95% confidence limits=1.4-4.7) compared 
with never users. However, no dose-response relationship was 
found; even the group of women who had used DMPA for less 
than 1 year had an elevated RR estimate (RR =2.3; 95% confidence 
limits=1.0-5.1). In contrast, OC users had no elevation in RR 
compared with never users (RR=1.2; 95% confidence limits= 
0.8-1.8). The results of the DMPA analysis are inconclusive. Before 
decisions are made on whether to continue providing this effective 
contraceptive method, other ongoing studies will need to confirm 
of refute these findings.—JNCI 1987; 79:1247-1254. 
Approximately 2 million women worldwide currently 
use injectable DMPA for contraception (1). Although 
DMPA has yet to be directly linked to any human 
cancer, the possibility of such an association, especially 
with breast cancer, was one of the reasons the U.S. Food 
and Drug Administration denied approval of DMPA for 
contraceptive use in the United States (2). Because of 
concern about the failure to obtain such approval, many 
governments in recent years have withheld or with-
drawn approval of DMPA. Because DMPA has been 
used in Costa Rica for more than 15 years and OC use is 
widespread, Costa Rica offers an opportunity to exam-
ine the relationship between use of hormonal contracep-
tives and the development of breast and cervical cancers. 
Costa Rica has one of the highest prevalences of con-
traceptive use in Latin America; 65% of currently mar- 
. 
	
	 ried women 15-49 years of age reported currently using 
a contraceptive method in 1981 (3). DMPA was first used 
as a contraceptive method in Costa Rica around 1970, 
although it was not licensed for general distribution 
until 1973. By 1981, 11% of currently married women 
reported ever use of an injectable form of contraception, 
most of which was DMPA. OCs were introduced in 
Costa Rica in the early 1960's. They remain the most 
commonly used form of contraception. By 1981, 58% of 
currently married women reported ever use of OCs (3). 
In 1970 cancer was the fourth leading cause of death 
in Costa Rica but has recently moved to second place 
(4). Among Costa Rican women, deaths related to breast 
cancer have gradually increased to reach a mortality rate 
of 13 per 100,000 in 1983 (5). The yearly incidence of 
breast cancer in Costa Rican women older than 20 years 
of age is about 39 per 100,000 women. The incidence of 
breast cancer in U.S. white women tends to be two to 
three times higher than in Costa Rican women of the 
same age. 
In 1984 the Costa Rican Demographic Association 
conducted a nationwide, population-based, case-control 
study of breast and cervical cancers in collaboration 
with the Division of Reproductive Health at the Centers 
for Disease Control. Additional assistance was received 
from the Costa Rican Ministry of Health, the Costa 
Rican Social Security System, and Family Health Inter-
national. In this report we present results from analyses 
of the association between breast cancer and use of hor-
monal contraceptives. 
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SUBJECTS AND METHODS 
Cases.—Since 1977 the Costa Rican Ministry of Health 
has maintained a nationwide cancer registry (4). Since 
1980 all hospitals and private pathologists have agreed 
to report to the registry any hospitalizations or outpa-
tient biopsies associated with a cancer diagnosis. Death 
certificates and autopsy reports have provided additional 
sources of information. We examined the completeness 
of reporting to the cancer registry by linking a sample of 
gynecologic cancer cases from the 1983 Costa Rican 
National Hospital Discharge Summary to the cancer 
registry files. The registry contained information on 130 
of the 133 (97.7%) hospital discharges in the sample. The 
registry does not obtain information on cancer cases 
who obtain their diagnosis and treatment outside of the 
country, although these are thought to represent a small 
proportion of cancers developing in Costa Ricans. 
To decrease the time required for data collection, we 
elected a method of retrospective enrollment of cancer 
cases. From the National Tumor Registry records, we 
chose all women with breast or cervical cancer, newly 
diagnosed between January 1, 1982, and March 31, 1984, 
who were 25-58 years of age at the time of diagnosis. 
From these records, 256 women were eligible for enroll-
ment as breast cancer cases. 
Controls.—Because the cases were ascertained from a 
population-based registry, we chose a population-based 
method to select the control group. We used a multi-
stage, probability household survey throughout Costa 
Rica to select controls, at which time cases and controls 
were interviewed. The survey and interviews were con-
ducted between September 1984 and February 1985. The 
sampling frame used for the survey was based on maps 
and preliminary results from the June 1984 census. A 
nationwide sample of census sectors had been selected at 
random before the survey began. Each sector contained 
approximately seven households. From these house-
holds, all women 25-59 years of age at the time of survey 
were eligible to be selected as controls. In the final con-
trol selection, women in older age groups were over-
sampled so that the age distribution of the controls 
would be frequency matched to the age distribution of 
the combined group of all cancer cases in the study. 
During the survey, 938 women were selected as potential 
controls. 
Interviews.—Cases and controls were interviewed in 
their homes with the use of a standard questionnaire 
modified from the Cancer and Steroid Hormone Study 
(6). The interviews were conducted by female inter-
viewers who had undergone a week-long training course. 
The interviews lasted about 45 minutes and gathered 
extensive information concerning the women's repro-
ductive, medical, and sexual histories. A calendar of life 
events was used to assist recall of contraceptive use up to 
the time of interview (6). 
If a woman reported having used OCs, but had never 
used them for at least 3 consecutive months, dates of her 
OC use were not recorded. If a woman reported ever 
using an injectable contraceptive, she was asked the type  
of injection. Only if she specifically reported use of 
DMPA or a 3-month injectable contraceptive was she 
considered to have used DMPA. 
Only 66.8% of the eligible breast cancer cases were 
interviewed (table 1); death was the major reason that 
women eligible to be cases were not interviewed (19.5%). 
The interview completion rate among women selected 
to be controls was 92.8%. 
Using data from the tumor registry, we compared the 
breast cancer cases who were interviewed with those who 
were not interviewed. Cases not interviewed were slightly 
more likely to have been diagnosed in 1982, to be 
younger, to be from San Jose, and to have an unspeci-
fied tumor type; the noninterviewed cases were less 
likely to have access to a telephone (25.9% compared 
with 32.7%), suggesting that, as a group, they may have 
had a lower socioeconomic status. 
We assessed the representativeness of the interviewed 
controls by comparing them with a nationwide sample 
of women obtained during two recent surveys. The age \ 
distribution of the interviewed controls, after adjustment • - 
for oversampling, was similar to the expected age distri-
bution based on the 1984 census. Furthermore, the dis-
tribution of controls by education, marital status, and 
contraceptive use closely matched the distribution 
reported in a 1981 survey (3). 
Definitions.—Because of the retrospective enrollment 
of the case group, we established before data analysis 
began an index date to ensure that exposures and other 
events that occurred after this date were not included in 
our analyses. For a case, the index date was her date of 
diagnosis recorded by the cancer registry; for a control, 
the index date was February 15, 1983, the halfway point 
in the 27-month period of case eligibility. We had 
information available so that the following variables 
used in this analysis could be adjusted for index date: all 
variables characterizing DMPA and OC exposure, age, 
parity, history of benign breast disease, menopausal 
status, history of breast-feeding, and age at first full-term 
pregnancy. 
For each woman who reported ever using DMPA orb 
using OCs for at least 3 consecutive months, we used 
information from the life calendar to characterize and 
quantify her hormonal contraceptive usage, up to her 
index date. We determined: 1) duration of use—total 
months of use, whether intermittent or continuous (one 
injection of DMPA was considered to provide 3 mo of 
TABLE 1.—Interview outcome for breast cancer cases and controls 
Interview outcome Cases Controls 
No. Percent No. Percent 
Completed 171 66.8 870 92.8 
Refused 9 3.5 21 2.2 
Deceased 50 19.5 
Unknown address 19 7.4 
Not at home 1 0.4 32 3.4 
Other 6 2.3 15 1.6 
Total 256 928 
S 
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use); 2) time since first use-number of months since 
first use; 3) time since last use-number of months since 
last use; and 4) age at first use. If a woman did not know 
all her dates of use, unknown values were assigned to 
the above variables. If a woman reported using DMPA 
or OCs, but the first use of the method occurred after her 
index date, she was considered to have never used the 
method. 
Using a method developed at the University of Costa 
Rica, we assigned a socioeconomic status index ranging 
from 0 to 17, based on the reported possession of 8 major 
household appliances. A woman had a history of benign 
breast disease if she reported breast surgery for a biopsy 
of a cyst or lump that did not result in a mastectomy. A 
woman had a first-degree family history of breast cancer 
if she reported that her mother, sister, or daughter had a 
history of breast cancer. 
Analysis.-We excluded from the control group 42 
women whose ages at index date were not between 25 
and 58 years and 2 women who reported previous mas-
tectomies. This left 171 cases and 826 controls available 
for the breast cancer analysis. 
We used logistic regression models (7, 8) containing 
the exposure of interest (either DMPA or OC use) and 
age at index date to control individually for the follow-
ing potentially confounding factors: education, geo-
graphic region of residence, socioeconomic status index, 
marital status, weight, parity, menopausal status, use of 
OCs, use of DMPA, history of benign breast disease, age 
at first full-term pregnancy, history of breast-feeding, 
self-reported history of infertility, first-degree family his-
tory of breast cancer, and reported number of breast 
examinations by a physician or nurse before 1982. The 
following variables were found to distort the risk esti-
mates associated with one or both exposures: age, parity, 
region of residence, socioeconomic status index, marital 
status, menopausal status, history of breast-feeding, age 
at first full-term pregnancy, and DMPA use (in the OC 
analysis). The final logistic regression models contained 
age (as a continuous variable), parity (continuous), 
socioeconomic status index (continuous), and DMPA 
use (ever, never), since simultaneously controlling for 
these factors eliminated the confounding effects pro-
duced by the other variables. 
RESULTS 
Table 2 presents various demographic and reproduc-
tive characteristics of the breast cancer cases and con-
trols. Recall that controls were selected to be frequency 
matched to the age distribution of the combined group 
of cervical and breast cancer cases. Because the cervical 
cancer case group was substantially younger than the 
breast cancer case group, the controls were younger than 
the breast cancer cases. Therefore, we present the percent 
distribution of characteristics of the control group 
standardized to the age distribution of the breast cancer 
case group. Compared with controls, a greater propor-
tion of breast cancer cases had a high socioeconomic 
status and education level, lived in the capital city of 
TABLE 2.-Percent distribution of characteristics of breast 
cancer cases and controls 
Characteristic 
Percent distribution 
Cases 
(n=171) 
Controls 
(n=826) 
Age at index date, yr 
25-34 9.9 37.3 
35-39 14.0 15.6 
40-44 19.3 13.6 
45-49 20.5 13.7 
50-54 22.8 13.8 
55-58 13.5 6.1 
Region of residence" 
San Jose 46.8 35.3 
Central Valley 31.6 32.0 
Other urban areas 10.5 10.0 
Other rural areas 11.1 22.7 
Education, yr"  
<6 40.9 54.9 
6 24.0 21.3 
>6 35.1 23.7 
Socioeconomic status index" 
Low (0-3) 29.8 43.6 
Medium (4-8) 29.8 29.8 
High (9-17) 40.4 26.6 
Marital status" 
Currently married 54.4 62.0 
Previously married 14.6 17.2 
Cohabiting 6.4 5.3 
Single 24.6 15.4 
Parity" 
0 17.0 8.7 
1-2 24.0 18.4 
3-4 28.1 22.7 
>5 31.0 50.1 
Unknown 0.0 0.1 
Age at first full-term pregnancy, yr° 
Nulliparous 17.0 8.7 
<20 20.5 32.9 
20-24 40.3 34.1 
25-29 15.8 15.9 
30 6.4 8.3 
Unknown 0.0 0.1 
History of benign breast cliseaseo 
No 87.7 96.5 
Yes 8.2 3.5 
Unknown 4.1 <0.1 
Family history of breast cancer" 
No 87.7 88.8 
Yes 7.0 5.1 
Unknown 5.3 6.1 
Menopausal status" 
Premenopausal 67.8 62.4 
Post-natural 22.8 29.3 
Post-surgical 8.8 8.1 
Unknown 0.0 0.2 
Ever breast fed?" 
Nulliparous 17.0 8.7 
No 11.7 9.6 
Yes 71.3 81.2 
Unknown 0.0 0.6 
No. of breast examinations by a health 
provider before 1982" 
0 51.5 54.0 
1-4 26.9 33.0 
5-9 6.4 5.2 
10 15.2 7.3 
Unknown 0.0 0.5 
"Distribution of the control group standardized to the age dis-
tribution of the case group. 
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Duration of DMPA use No. of cases No. of controls 
Odds ratio 95% confidence 
interval Crude Adjusted 
Never 129 724 1 1 Referent 
Ever 19 49 2.2 2.6 1.4-4.7 
<12 mo 9 30 1.7 2.3 1.0-5.1 
12-23 mo 5 7 4.0 4.4 1.2-15.7 
24-71 mo 5 8 3.5 3.4 1.0-11.0 
>72 mo 0 4 0 0 
a  Exclusions: 23 cases and 50 controls 55-58 yr old, 2 controls with unknown duration of DMPA use, and 1 control with unknown parity. 
b Adjusted for age, parity, and socioeconomic status. 
San Jose, were single, had low parity, and reported a 
history of benign breast disease. 
DMPA Use and Breast Cancer Risk 
Because only 1 case and no controls 55 years or older 
had ever used DMPA, we restricted the DMPA analysis 
to women 25-54 years of age. Although few cases or con-
trols had ever used DMPA, we found that women who 
had ever used DMPA had a statistically significant ele-
vated risk of breast cancer of 2.6 (95% confidence lim-
its = 1.4-4.7) compared with women who had never used 
DMPA (table 3). 
Any dose-response effect was difficult to evaluate 
because of the small number of DMPA users. However, 
we found no such relationship; i.e., there was no effect 
of increasing duration of DMPA use on breast cancer 
risk (table 3). Women who had used DMPA for less than 
12 months had an elevated risk compared with never 
users, whereas the longest-term users had a risk estimate 
of zero. 
The RR of breast cancer associated with DMPA use 
was highest for women who had the longest time since 
first use (t-Able 4). Women who first used DMPA 10 or 
more years before the index date had a fourfold risk of 
breast cancer compared with never users. The risk of 
breast cancer associated with DMPA use was elevated 
regardless of the time since last use (table 4) or age at 
first use (not shown). 
We found no important differences in the association 
between DMPA use and breast cancer among various 
subgroups of women (table 5). Women of various age, 
parity, and socioeconomic status levels all had elevated 
RR estimates. Insufficient numbers of DMPA users 
existed to examine the effects of OC use, history of 
benign breast disease, and family history of breast cancer 
on the DMPA-breast cancer association. 
OC Use and Breast Cancer Risk 
Compared with women who reported never using 
OCs, women who reported ever using OCs had a risk of 
developing breast cancer of 1.2 (0.8-1.8) (table 6). Note 
that women were excluded who had never used OCs for 
3 or more consecutive months, since we could not be 
certain that any of that use had occurred before their 
index date. Women who had used OCs for a total dura-
tion of 36-59 months had an elevated RR estimate of 2.0 
(1.0-4.1); women in other duration categories had no 
increased risk. Women with the longest duration of OC 
use had an RR of 1.0 (0.4-2.6). There were no effects of 
time since first or last OC use (table 7) or age at first OC 
use (not shown). Women who had first used OCs before 
the age of 25 had a risk of 0.9 (0.4-1.7) compared with 
never users. 
A woman's age at index date did not affect the associa-
tion between OC use and breast cancer (table 8). Nulli-
parous women had an elevated RR; however, there were 
only 3 cases and 3 controls who had ever used OCs in 
the nulliparous group. 
TABLE 4.—Time since first and last use of DMPA by breast cancer cases and controls° 
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TABLE 3.—Duration of DMPA arse by breast cancer cases and controls° 
DMPA use No. of cases No. of controls Adjusted odds ratio(' 95% confidence interval 
Never 129 724 1 Referent 
Time since first use, yr 
<5 5 19 2.1 0.7-5.8 
5-9 6 18 2.0 0.7-5.6 
8 12 4.0 1.5-10.3 
Time since last use, yr 
<5 8 26 2.2 1.0-5.2 
>5 11 23 2.9 1.3-6.5 
Exclusions: 23 cases and 50 controls 55-58 yr old, 2 controls with unknown time since first and last DM PA use, and 1 control with unknown 
parity. 
b Adjusted for age, parity, and socioeconomic status. 
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TABLE 5.-DMPA use and breast cancer risk by selected characterist. ics4  
Characteristic 
Ever user Never user 
Adjusted 
odds ratiob 
95% confidence 
interval No. of 
cases 
No. of 
controls 
No. of 
cases 
No. of 
controls 
Age at index date, yr 
25-39 5 27 36 409 2.4 0.8-6.6 
40-44 5 10 28 102 2.0 0.6-6.5 
45-49 6 6 29 107 5.4 1.6-18.5 
50-54 3 8 36 106 1.3 0.3-5.3 
Parity 
0 2 1 25 74 2.9 0.2-38.8 
1-2 3 9 32 210 2.1 0.5-9.0 
3-4 5 20 35 187 1.7 0.6-5.0 
>5 9 21 37 253 3.4 1.4-8.2 
Socioeconomic status 
Low 9 27 37 325 2.8 1.2-6.6 
Medium 6 14 39 213 3.1 1.1-9.0 
High 4 10 53 186 1.3 0.4-4.6 
Region of residence 
San Jose 10 16 58 250 2.6 1.1-6.3 
Central Valley-other urban areas 3 19 59 321 1.1 0.3-3.9 
'•Other rural areas 6 16 12 153 5.4 1.7-17.0 
No. of breast examinations 
0 10 24 65 373 2.6 1.1-6.1 
1-2 5 11 18 171 4.0 1.2-13.3 
3 4 16 46 177 1.4 0.4-4.5 
a Exclusions: 23 cases and 50 controls 55-58 yr old and 1. control with unknown parity. 
6 In each characteristic stratum, ever users of DMPA are compared with never users. Each model includes age, parity, socioeconomic status, 
the variable of interest, and the appropriate interaction terms. 
TABLE 6.-Duration of OC use by breast cancer cases and controle 
Duration of OC use No. of cases No. of controls 
Odds ratio 95% confidence 
interval Crude Adjusted b 
Never 97 427 1 1 Referent 
Ever 58 321 0.8 1.2 0.8-1.8 
<12 mo 13 72 0.8 1.2 0.6-2.4 
12-35 mo 12 87 0.6 0.8 0.4-1.5 
36-69 mo 14 52 1.2 2.0 1.0-4.1 
60-119 mo 13 81 0.7 1.2 0.6-2.3 
•120 mo 6 29 0.9 1.0 0.4-2.6 
Exclusions: 13 eases and 67 controls without a.3 consecutive mo of OC use, 3 cases and 10 controls with unknown duration of OC use, and 
1 control with unknown parity. 
b Adjusted for age, parity, socioeconomic status, and ever use of DMPA. 
TABLE 7.-Time since first and last use of OCs by breast cancer cases and controls° 
OC use No. of cases No. of controls Adjusted odds ratiob 95% confidence interval 
Never 97 427 1 Referent 
Time since first use, yr 
<10 17 145 1.2 0.6-2.2 
10-14 18 116 0.9 0.5-1.7 
15-19 19 42 1.9 1.0-3.6 
a-20 4 18 0.7 0.2-2.3 
Time since last use, yr 
<5 20 172 1.1 0.6-2.0 
5-9 18 82 1.1 0.6-2.1 
10 20 67 1.2 0.7-2.2 
'Exclusions: 13 cases and 67 controls without ..?23 consecutive mo of OC use, 3 cases and 10 controls with unknown time since first and last 
OC use, and 1 control with unknown parity. 
b Adjusted for age, parity, socioeconomic status, and ever use of DMPA. 
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TABLE 8.-OC use and breast cancer risk by selected characteristics' 
Characteristic 
No. of ever users No. of never users Adjusted 
odds ration 
95% confidence 
interval Cases Controls Cases Controls 
Age at index date, yr 
25-34 6 161 8 116 0.6 0.2-1.7 
35-39 15 64 8 51 1.5 0.6-3.8 
40-44 16 48 11 58 1.4 0.6-3.4 
45-49 13 29 20 77 1.4 0.6-3.4 
50-58 11 29 50 125 0.8 0.4-1.9 
Parity 
0 3 3 24 74 5.0 0.7-37.8 
1-2 15 112 22 96 0.9 0.4-2.0 
3-4 19 117 23 81 0.8 0.4-1.7 
5-6 12 45 10 62 3.0 1.1-8.1 
>7 12 54 18 114 1.6 0.7-3.7 
Socioeconomic status 
Low 21 148 28 196 1.4 0.7-2.8 
Medium 17 102 30 124 1.1 0.5-2.3 
High 23 81 39 107 1.1 0.6-2.0 
Region of residence 
San Jose 36 129 39 135 1.5 0.8-2.6 
Central Valley 
Other urban areas 
9 
8 
105 
38 
40 
7 
145 
43 
0.4 
3.0 
0.2-1.0 
0.9-9.7 --) 
Other rural areas 8 59 11 104 1.7 0.6-5.0 
No. of breast examinations 
0 25 146 56 248 1.3 0.7-2.4 
1-2 10 91 16 96 0.9 0.4-2.1 
>3 26 93 25 81 1.1 0.6-2.3 
a Exclusions: 13 cases and 67 controls without 
	 consecutive mo of OC use and 1 control with unknown parity. 
n In each characteristic stratum, ever users of OCs are compared with never users. Each model includes age, parity, socioeconomic status, 
ever use of DMPA, the variable of interest, and the appropriate interaction terms. 
Characteristics of Exposure Among Controls 
To better characterize hormonal contraceptive use in 
Costa Rica, we examined exposure by selected charac-
teristics among the control group, standardized to the 
age distribution of the breast cancer case group (table 9). 
Ever use of DMPA was approximately equal across all 
age groups from 25 to 54, whereas ever use of OCs 
decreased with increasing age. DMPA use was slightly 
more common in the areas outside the Central Valley 
and among women of lower socioeconomic status. OC 
use was slightly more common among women living in 
San Jose and increased with increasing socioeconomic 
status. Women of low parity were less likely to have 
used either method of contraception. 
DISCUSSION 
One-third of the women with breast cancer eligible for 
the study could not be interviewed; about 20% were not 
interviewed because they had died. If DMPA use prior to 
diagnosis were associated with an increased possibility 
of breast cancer survival, then DMPA users would be 
overrepresented in our interviewed case group, which 
could account for at least part of the increased RR 
found_ This is a reasonable concern, since DMPA is used 
as a treatment for advanced breast cancer. Assuming that 
none of the deceased cases had ever used DMPA, the 
crude odds ratio compared with never users would be 1.5, 
still a positive association. 
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TABLE 9.-Percent distribution of ever use of hormonal contraceptives 
among control women by selected characteristics 
Characteristic 
Percent 
Ever use of DMPA a Ever use of OCs 
Age at index date, yr 
25-34 6.2 58.1 
35-39 6.2 56.0 
40-44 8.9 45.3 
45-49 5.3 27.4 
50-54 7.0 22.9 
55-58 0.0 10.2 
Parity b  
0-1 2.3 13.0 
2-3 8.4 47.5 
>4 7.9 37.9 
Socioeconomic status b  
Law 7.9 32.0 
Medium 6.1 36.5 
High 5.7 38.4 
Region of residencen 
San Jose 7.1 40.4 
Central Valley 4.0 34.7 
Other urban areas 12.4 35.7 
Other rural areas 7.6 25.4 
All control womenn 6.8 35.0 
a Excludes controls 55-58 yr old, as none had ever used DMPA. 
'Adjusted to age distribution of breast cancer case group (for 
DMPA use, cases 25-54 yr; for OC use, cases 25-58 yr). 
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If ever use of DMPA were associated with an increased 
likelihood that breast cancer might be detected, our 
results could be biased in a positive direction. That the 
risk associated with DMPA use was lower for those 
women with more frequent breast examinations and 
with high socioeconomic status supports this possibility 
(see table 5). Table 10 presents the percentage of women 
in the control group who reported ever having a breast 
examination before 1982 performed by a health pro-
vider, stratified by ever use of hormonal contraceptives 
and by selected characteristics. Although fluctuations in 
the percentages occurred, there were no discernible pat-
terns of differences between DMPA users and never users 
of DMPA in the percentage of women with breast 
examinations, by age, parity, region, or socioeconomic 
status. In contrast, OC users may have been more fre-
quently screened than never users of OCs, especially 
among the older age groups and women of higher parity 
and socioeconomic status. Although hampered by the 
small number of DMPA users, the lack of major differ-
ences in the possibility of tumor detection between con-
trol users and nonusers argues that a detection bias in 
the DMPA analysis is unlikely to account for all the ele-
vated RR found. 
Inaccurate recall of DMPA use would result in a 
spurious increase in the RR only if there were differen-
tial misclassification, with cases incorrectly classified as 
DMPA users more often than controls. Nondifferential 
misclassification of the exposure generally should bias 
the RRs toward 1.0. The retrospective enrollment of the 
TABLE 10.-Percentage of control women ever having a breast 
examination by ever use of hormonal contraceptives and by 
selected characteristics 
Characteristic 
Percent with examination 
DMPA 
uses 
No DMPA 
use' 
OC 
use 
No OC 
use 
Age at index date, yr 
25-34 52.6 50.2 52.8 46.6 
35-39 87.5 56.2 61.5 51.0 
40-44 70.0 52.9 56.2 53.4 
45-49 16.7 41.1 48.3 36.4 
50-54 25.0 35.8 62.5 27.2 
55-58 80.0 36.4 
Parityb 
0-1 16.2 42.9 44.2 36.6 
2-3 77.7 57.9 57.3 51.4 
>4 45.4 42.4 54.6 37.0 
Socioeconomic status 
Low 30.6 31.2 39.3 27.6 
Medium 83.2 50.6 70.4 45.4 
High 36.4 66.2 75.0 57.4 
Region of residenceb 
San Jose 48.0 52.8 70.5 45.4 
Central Valley 69.2 52,6 60.2 46.8 
Other urban areas 58.1 51.0 55.4 49.7 
Other rural areas 25.8 24.7 23.0 23.3 
All control womenb 50.4 46.1 59.3 40.1 
a Excludes control women 55-58 yr old, as none had ever used 
DMPA. 
'Adjusted to age distribution of breast cancer case group (for 
DMPA use, cases 25-54 yr; for OC use, cases 25-58 yr). 
case group made classifying contraceptive exposure dif-
ficult because we were only interested in exposure before 
cancer diagnosis among cases and before February 15, 
1983, among controls. Recall that the interviewers did 
not use the index date when collecting information from 
cases or controls; rather, contraceptive history up to the 
time of interview was collected from all women in the 
study. Breast cancer cases were interviewed up to 
3 years after diagnosis; controls were interviewed about 
18 months after the control group's index date. Use of a 
life calendar to obtain contraceptive exposure informa-
tion probably lessened misclassification of contraceptive 
exposure (9). 
To assess the adequacy of the exposure information 
among control women, we compared the prevalence 
rates of ever use of DMPA and OCs in February 1983 
among ever-married women in the control group with 
the prevalence rates determined from a 1981 nationwide 
survey of currently married women in Costa Rica (3). 
We found almost identical prevalence rates in the two 
studies. No independent data source exists to assess the 
exposure information among the breast cancer cases. 
Although the controversy concerning the DMPA-breast 
cancer association has not received widespread attention 
in Costa Rica, the possibility remains that a systematic 
difference in recall of contraceptive use may have existed 
between cases and controls, which could have biased the 
results. 
Although we have not identified any obvious bias, the 
elevated breast cancer risk among women who used 
DMPA for only a short period of time suggests that 
some bias that we have not been able to characterize may 
still account for the overall positive association. A 
cumulative effect of small biases associated with the fol-
lowing could conceivably result in a positive association 
such as we have found: 1) failure to interview 33% of the 
eligible cases, 2) possible differential detection of tumors 
according to DMPA use, and 3) misclassification of 
DMPA exposure. Moreover, the small number of DMPA 
users enrolled in the study increases the likelihood that 
chance could account for part of the elevated risk 
estimate. 
Other studies have failed to document an association 
between DMPA use and breast cancer in women (10-12). 
In 1986 results were published from an ongoing, multi-
national, hospital-based, case-control study of steroidal 
contraceptives and various cancers, conducted under the 
auspices of the WHO (12). The WHO investigators 
reported that ever use of DMPA was associated with an 
RR estimate for breast cancer of 1.0 (0.7-1.5) based on 
39 case users and 557 control users. No increase in risk 
was seen for even long-term users. Differences in study 
design and populations probably explain some of the 
discrepancies in the results between the WHO study and 
this one. 
The results from our study in Costa Rica support the 
numerous scientific studies that have found that OC use 
does not appear to increase breast cancer risk. This is 
one of the first studies on this issue performed outside of 
North America and Europe. Results from a Los Angeles 
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study published in 1983 by Pike et al. (13) raised the 
possibility that use of certain "high-progestin" OC for-
mulations before the age of 25 increases the risk of breast 
cancer. We found no increase in breast cancer risk asso-
ciated with ever use of OCs before age 25, although we 
lacked a sufficient number of case users to examine the 
effect of duration of use before age 25. Because we did 
not consider use of specific OC formulations, our results 
do not directly address the concerns raised by Pike et al. 
However, as the most commonly used OC formulation 
in Costa Rica (50 isg ethinyl estradiol/0.5 mg norgestrel) 
has been one of those classified as "high progestin" by 
Pike et al., we believe it unlikely that an elevated risk 
would exist for this subgroup of OC users. 
Results from another study published in 1983 (14) 
found that breast cancer risk was increased for women 
who had used OCs before their first full-term pregnancy. 
Only 2 cases and 34 controls in our study had ever used 
OCs before their first full-term pregnancy; the usual 
practice in Costa Rica is to delay contraceptive use until 
after 1 or more children have been born (3). 
In summary, in this study of Costa Rican women, we 
found a statistically significant elevated risk of breast 
cancer associated with ever use of DMPA, although no 
dose-response effect was seen. In contrast, we found no 
association between OC use and breast cancer. Primarily 
because of the small number of DMPA users and the 
lack of a dose-response relationship, the results of our 
DMPA analysis must finally be regarded as inconclu-
sive. Before decisions are made on whether to continue 
providing this effective contraceptive method, other 
ongoing studies will need to confirm or refute these 
findings. 
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